Erorr
Erorr
Erorr

Pasbion News

Erorr

Aeterna CEO Dodd out as company reviews options

It's been a big week for Aeterna Zentaris. Fresh from the news that its lead pipeline candidate is back under FDA review with a verdict due before year-end, it's just announced the departure of CEO David Dodd and a strategic rethink.

Read More

News of Note—Biotech IPOs; CHMP knockbacks

Check out Friday's dose of biotech's news of note.

Read More

MHRA to move HQ to same area as EMA’s London digs

The United Kingdom’s drug regulator is moving its headquarters to within half a mile of the EMA’s current home. Staffers are set to move to their new digs in east London in the middle of next year, shortly before their peers at the EMA are scheduled to leave the city.

Read More

Targeting inflammation could treat metabolic syndrome's many symptoms

There is no silver bullet to treat metabolic syndrome, a collection of maladies that raise the risk for heart disease and diabetes. But Feinstein Institute-led researchers have come a step closer by using an Alzheimer’s drug to reduce inflammation in people with the syndrome.

Read More

Ironwood slips as heartburn data underwhelm investors 

A phase 2b trial of Ironwood Pharmaceuticals’ IW-3718 has met its primary endpoint, teeing the heartburn candidate up to move into a pivotal trial and on to blockbuster sales. But the positive narrative spun by Ironwood’s management failed to convince investors, who seized on perceived underwhelming efficacy data and drove down the company’s stock.

Read More

Attacking muscle diseases like ALS by clearing protein clumps

Researchers have identified a process that promotes the protein clumping characteristic of degenerative diseases. While the work is in early stages, a team from the University of North Carolina envisions an injectable or oral drug that could treat amyotrophic lateral sclerosis and sporadic inclusion body myositis.

Read More

News of Note—Trevena CMO exit; AMO deal; Kala IPO; AliveCor-Mayo pact

Check out the rest of Thursday's news of note.

Read More

Sanofi offers Ablynx billions of biobucks for nanobody partnership

Belgian biotech Ablynx just signed a potentially lucrative new deal with Sanofi that could be worth an eye-watering €2.4 billion, although just €23 million of that comes up front.

Read More

Roche dumps Oryzon’s epigenetic AML, solid tumor drug 

Roche has jettisoned Oryzon’s treatment for acute myeloid leukemia (AML) and solid tumors from its pipeline. The decision to dump lysine-specific demethylase-1 inhibitor ORY-1001 wiped as much as 30% off Oryzon’s stock price as investors digested the loss of the $500 million-plus deal.

Read More

Theravance COPD drug clears safety study, setting up NDA

Theravance Biopharma and Mylan are still on course to file for approval of their nebulized chronic obstructive pulmonary disease (COPD) therapy in the fourth quarter after posting 12-month safety data. The trial suggests revefenacin has a tolerable safety profile comparable to that of Boehringer Ingelheim’s bronchodilator Spiriva.

Read More

Novartis, Sanofi-backed NeuroVia closes $14M series A for X-ALD work

Sanofi Genzyme's and Novartis’ venture arms have backed NeuroVia, an upstart that wants to help treat the rare CNS disorder X-linked adrenoleukodystrophy.

Read More

News of Note—Dodgy stem cell clinics; New CMO for Context; UroGen payday

Check out the rest of Wednesday's news of note.

Read More

EU watchdog asks if drugmakers influence EMA decisions

The European Union is investigating whether presubmission meetings with the EMA enable drug companies to influence marketing authorization approval decisions. Officials at the EMA must now allay concerns their meetings with sponsors introduce a source of bias into their decision-making. 

Read More

Lilly firms up Adimab R&D alliance, bringing its Ab platform in-house

Eli Lilly likes what it sees in Adimab's antibody R&D platform, opting to roll it out at sites in San Diego and New York to help its antibody discovery and optimization activities.

Read More

Japan’s Fujifilm sees phase 2 flop for Alzheimer’s candidate

In an all-too-familiar release, Fujifilm announced this morning that it has become the latest in a long line of biopharmas to see a failure for its Alzheimer’s drug.

Read More

Vertex cystic fibrosis drugs ace clinical trials, sparking 26% stock price surge

Vertex’s triple-combination cystic fibrosis regimens have aced early-phase clinical trials. The strong efficacy seen in the trials suggests the combinations can treat most cystic fibrosis patients, opening the door to an expanded multibillion-dollar market.

Read More

News of Note—Nektar’s sweet data; Zymeworks bonus; Alzheimer’s pipeline

Check out the rest of Tuesday's news of note.

Read More

Shire pens bispecific hemophilia R&D deal with Novimmune

As the hemophilia market builds and tensions fray, Shire has signed a new licensing deal targeting bispecific antibodies. The Ireland-based drugmaker announced a tie-up with Swiss biotech Novimmune for a worldwide license to work on a preclinical candidate for hemophilia A.

Read More

Kleo taps PeptiDream for help with immuno-oncology programs

Kleo Pharmaceuticals' new CEO Douglas Mannion has made his first play, cutting a deal with Japan's PeptiDream to step up its pursuit of immuno-oncology drug candidates.

Read More

Abzena licenses PSMA antibodies to Telix to create cancer-targeting radioactive drugs

Abzena has licensed its prostate-specific membrane antigen (PSMA) antibodies to Telix Pharmaceuticals. Telix has committed about $65 million (€56 million) in license fees and milestone payments in return for the exclusive right to use the antibodies to guide radioactive payloads to tumors.

Read More

Paratek antibiotic hits endpoints in phase 3, teeing up NDA

A phase 3 trial of an oral formulation of Paratek Pharmaceuticals’ antibiotic omadacycline has met its primary endpoints. The third late-phase success sets Paratek up to file for approval with the FDA, although incidence of vomiting and nausea cast a shadow over the data. 

Read More

CymaBay takes a peek at liver disease candidate data

Small cap CymaBay Therapeutics has taken a look at its ongoing midstage test for its liver med seladelpar, and says it’s happy with what it sees.

Read More

Backers put $12.7M behind Enterin's Parkinson's disease approach

Philadelphia biotech Enterin has raised $12.7 million in funding to pursue its hypothesis that Parkinson's disease originates in the gut, not the brain.

Read More

U.K. commits £86M to get medical advances into NHS faster

The United Kingdom has put together an £86 million ($112 million) package of funding to cut the time it takes for drugs and other medical advances to reach patients. Officials are making the cash available to start implementing Accelerated Access Review recommendations the U.K. sees establishing it as the first port of call for drug development in Europe.

Read More

Safety scare prompts FDA to reject Amgen’s romosozumab

The FDA has rejected Amgen’s application for approval of osteoporosis candidate romosozumab. Officials knocked back the filing after phase 3 data linked the sclerostin-targeting antibody to an increased risk of cardiovascular adverse events.

Read More

Contact Us

PASBION HEALTHCARE INC
1747 S. Douglass Road, Suite C
Anaheim, California 92806
714.231.9876

PASBION HEALTHCARE INC
Building No X111/2a. M.C Road,
Kalady-683 574,Ernakulam Dist,
Kerala, India
+91 -8606 44 88 90
info@pasbion.com

Contact Us

Erorr

PASBION HEALTHCARE INC

1747 S. Douglass Road, Suite C

Anaheim, California 92806

714.231.9876